{"id":629163,"date":"2024-08-01T10:34:56","date_gmt":"2024-08-01T14:34:56","guid":{"rendered":"https:\/\/www.singlecare.com\/blog\/?p=629163"},"modified":"2024-10-25T09:49:48","modified_gmt":"2024-10-25T13:49:48","slug":"victoza-alternatives","status":"publish","type":"post","link":"https:\/\/www.singlecare.com\/blog\/victoza-alternatives\/","title":{"rendered":"Victoza (liraglutide) alternatives: What can I take instead of Victoza?"},"content":{"rendered":"

Victoza (liraglutide) is a glucagon-like peptide-1 (GLP-1) agonist medication approved by the U.S. Food and Drug Administration (FDA) to help manage Type 2 diabetes by mimicking a natural hormone for blood sugar control. Victoza use comes with a black box warning due to potential risks that include acute pancreatitis and an increased risk of thyroid cancer. Gastrointestinal side effects, such as diarrhea, nausea, vomiting, and possible limitations in insurance coverage, may lead some patients to consider alternative treatment options.<\/span><\/p>\n

What can I take in place of Victoza?<\/span><\/h2>\n

Approximately <\/span>10% of the American population<\/span><\/a> has diabetes mellitus, with the vast majority living with Type 2 diabetes. While both Type 1 and Type 2 diabetes result in blood sugar level issues, the <\/span>main difference<\/span><\/a> is that Type 2 diabetes develops over years and most commonly affects adults 45 years of age or older. New and effective options are continually emerging for managing blood sugar in <\/span>Type 2 diabetes<\/span><\/a>. Victoza is available only as an injectable drug and is a first-line prescription for those with additional medical conditions like heart disease, increased risk of heart attack, or kidney function problems. <\/span><\/p>\n

A benefit of the GLP-1 receptor agonist class of medication is its low likelihood of causing low blood sugar as a side effect when used as monotherapy. However, many more medication options are available for those who are unable or do not want to self-inject or tolerate the common side effect profile of Victoza. The alternative treatments include other types of <\/span>GLP-1 agonists<\/span><\/a>, plus other medication classes like biguanides, sulfonylureas, sodium-glucose co-transporter 2 (SGLT2) inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors. Insulin also remains an option. <\/span><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
\n

Compare Victoza alternatives<\/span><\/h2>\n<\/th>\n<\/tr>\n<\/thead>\n

Drug name<\/b><\/td>\nUses<\/b><\/td>\nDosage<\/b><\/td>\nSavings options<\/b><\/td>\n<\/tr>\n
Victoza (liraglutide) <\/span><\/td>\nType 2 diabetes mellitus treatment<\/span><\/td>\n\n
    \n
  • 0.6 mg SUBQ once daily for 1 week, then increase to 1.2 mg SUBQ once daily <\/span><\/li>\n
  • If glycemic control is not achieved, the dose may increase to a maximum of 1.8 mg SUBQ once daily<\/span><\/li>\n<\/ul>\n<\/td>\n
Victoza coupons<\/span><\/a> <\/span><\/td>\n<\/tr>\n
Ozempic (semaglutide) <\/span><\/td>\nType 2 diabetes mellitus treatment<\/span><\/td>\n\n
    \n
  • 0.25 mg SUBQ once weekly for 4 weeks, then increase to 0.5 mg SUBQ once weekly<\/span><\/li>\n
  • The dose may increase to 1 mg SUBQ once weekly after 4 weeks if needed to achieve optimal glycemic control<\/span><\/li>\n
  • It may further increase to 2 mg SUBQ once weekly after 4 weeks if necessary to achieve optimal glycemic control<\/span><\/li>\n<\/ul>\n<\/td>\n
Ozempic coupons<\/span><\/a><\/td>\n<\/tr>\n
Glumetza (metformin ER) <\/span><\/td>\nType 2 diabetes mellitus treatment; gestational diabetes mellitus treatment; ovarian hyperstimulation syndrome prevention; antipsychotic-induced weight gain treatment<\/span><\/td>\n\n
    \n
  • 500 mg to 1,000 mg once daily; maximum 2,000 mg per day<\/span><\/li>\n<\/ul>\n<\/td>\n
Glumetza coupons<\/span><\/a> <\/span><\/td>\n<\/tr>\n
Invokana (canagliflozin) <\/span><\/td>\nType 2 diabetes mellitus treatment<\/span><\/td>\n\n
    \n
  • 100 mg by mouth once daily; may titrate up to a maximum of 300 mg by mouth daily; special considerations for renal dysfunction<\/span><\/li>\n<\/ul>\n<\/td>\n
Invokana coupons<\/span><\/a> <\/span><\/td>\n<\/tr>\n
Tradjenta (linagliptin) <\/span><\/td>\nType 2 diabetes mellitus treatment<\/span><\/td>\n\n
    \n
  • 5 mg by mouth once daily<\/span><\/li>\n<\/ul>\n<\/td>\n
Tradjenta coupons<\/span><\/a><\/td>\n<\/tr>\n
Mounjaro (tirzepatide) <\/span><\/td>\nType 2 diabetes mellitus treatment<\/span><\/td>\n\n
    \n
  • 2.5 mg SUBQ once weekly for 4 weeks, then increase to 5 mg SUBQ once daily<\/span><\/li>\n
  • Dose may increase to 2.5 mg per week in 4-week increments up to a maximum of 15 mg per week<\/span><\/li>\n<\/ul>\n<\/td>\n
Mounjaro coupons<\/span><\/a> <\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Other alternatives to Victoza<\/span><\/h3>\n